Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials

2020171 citationsJournal Articlebronze Open Access

Authors

Romain Cohen · Sorbonne Université

Julien Taı̈eb · Université Paris Cité

Jack Fiskum · Mayo Clinic

Greg Yothers · University of Pittsburgh

Richard M. Goldberg · West Virginia University

Takayuki Yoshino · National Cancer Center Hospital East

Steven R. Alberts ·

Abstract

Adding oxaliplatin to FP improves OS and DFS in patients with MSI stage III CC. Compared with MSS, MSI patients experienced better outcomes in the N1 group but similar survival in the N2 group.

Topics & Keywords

Genetic factors in colorectal cancer Colorectal Cancer Treatments and Studies Colorectal Cancer Screening and Detection

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 39, Issue 6, pp. 642-651

DOI: 10.1200/jco.20.01600

Field-Weighted Citation Impact: 12.90